MAPT and Alzheimer disease: AD can now be diagnosed using validated in vivo biomarkers which serve as proxies for AD-related neuropathic changes: amyloid, tau, and neurodegeneration (ATN) [1,2,3], allowing researchers to investigate the entire AD syndromic spectrum rather than rely on specific clinical criteria.